G1-G2 (1994-2005)

N = 200

mOS (months) p value

G3 (2006-2011)

N = 201

mOS (months [CI]) p value

General condition (WHO)

≥2

10.3

0.9

5.78 [1.12 - 10.44]

<0.0001

<2

17.8

24.74 [19.87 - 29.6]

Absence of initial tumor complication

Yes

-

28.32 [21.83 - 34.8]

0.038

No

19.84 [15.25 - 24.43]

Metastases

Metachronous

14.7

0.28

35.97 [29.53 - 42.42]

<0.0001

Synchronous

11.4

13.37 [10.73 - 16]

Localisation of metastases

Liver

17.6

0.3

10.65 [12.11 - 21.19]

<0.0001

Lung

18

29.04 [5.41 - 52.67]

Peritoneum

33.2

12.22 [9.58 - 14.86]

Ovary

18.2

15.64 [12.55 - 18.72]

Normal liver function tests (%)

Yes

20.5

<0.001

24.87 [21.12 - 28.6]

0.007

No

12.3

10.45 [3.6 - 17.29]

Normal initial level of CEA (%)

Yes

24.5

0.01

33.67 [26.6 - 40.7]

<0.0001

No

15.1

18.66 [13.36 - 24]

Surgery of the primary tumor

Yes

-

15.05 [11.118.9]

0.001

No

5.88 [4.49 - 7.27]

Surgery of liver metastases

Yes

40.7

0.05

25.2 [15.69 - 34.71]

0.016

No

15.1

20.27 [13.02 - 27.52]

ORR after 3 cycles of first line CT

Yes

15.3

<0.0005

29 [21.86 - 36.2]

0.034

No

13.3

20.2 [13.8 - 26.7]

Folfiri ± bevazicumab as third line CT

-

22.75 [-]

0.031